{"ticker": {"uuid": "5d34df53-fa6f-440c-aec2-1a6b0cb980f5", "symbol": "BLCO", "name": "Bausch + Lomb Corp", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Medical Instruments & Supplies"}, "articles": [{"title": "Bausch + Lomb Launches EyeGility\u2122 Inserter Preloaded IOL Delivery System in the United States", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bausch-lomb-launches-eyegility-inserter-110000251.html", "source_name": "Business Wire", "published_at": "2026-07-16T11:00:00+00:00", "published_display": "16 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ophthalmology-devices-market-report-released-113000874.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T11:30:00+00:00", "published_display": "13 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BLCO Stock Drops After-Hours \u2014 Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQcVR2TktPdTV5TFB1LXBsS0FiVklodV9kZlZsc0U1QTNyQ2dvT2lXa1NIZFlVRTZORGFDS21rNll4bDM2SC1GdWlXcm45TENtQnUwcVAyd1NwVnA0V1VmM255OXBwZUNGQmItWEMyakJsYnJxaDNoWUFud25XQzdiVldkZldsaDFkWTlqazAyT0xzVDR0RkpLZXN2ZHRpRE83RTVqWk9TV2dtS1FTejhBYlBaMEpSRS1RMHl1SGlUMGNyQWp1T1JmMjVFeXNtUHJaamZQbw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-12T16:31:13+00:00", "published_display": "12 Jul 2026 16:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPYmtwbXNJUjlRc0owMHd3MDBQOFFhM1ppZWZmSkZVTVV0M1NVdDRKS2s5SDdaQndDZk81WHRXNTNZNGNVSHNPbVBQdURxdGhQSUxsLXRRRnZMZC1rSS1qXzMyUlFocTZ6TFA2OGNYSDBVeUtGUnpJWG1CZlRLV2U5ZmE0bWhIUGtmOXh6bExjZUlCanZJQ3c?oc=5", "source_name": "Market source", "published_at": "2026-07-10T21:27:20+00:00", "published_display": "10 Jul 2026 21:27", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Bausch + Lomb Corporation \u2013 NYSE:BLCO", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNOE05YnQ4Sk9xNVp1SXBsWUtYaVB3WFVhaEtwTkprbEY4TG5JVHJ4THV5ZlFtaFVVejBSVUc3d09kbW13VktnVl80eFpkUWstcWo3QzBLeFBCTTlvUmVkODlxaXdCeTJacUZoU2pNaEtTdmQtbjdsZW95MWpnbVVmU0tfblFOQjVUVU8wVEZsVU9ZWHBrd3hxd2dkc0xFRTA?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T11:37:40+00:00", "published_display": "10 Jul 2026 11:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb (BLCO) Could Be 57% Below Fair Value After Product Updates", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bausch-lomb-blco-could-57-061154578.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T06:11:54+00:00", "published_display": "10 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb Says Phase 2 Trial for Glaucoma Neuroprotective Candidate Fails to Meet Primary Endpoint", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bausch-lomb-says-phase-2-205707845.html", "source_name": "MT Newswires", "published_at": "2026-07-09T20:57:07+00:00", "published_display": "09 Jul 2026 20:57", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bausch-lomb-announces-phase-2-203000317.html", "source_name": "Business Wire", "published_at": "2026-07-09T20:30:00+00:00", "published_display": "09 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb Introduces Orphia\u2122, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bausch-lomb-introduces-orphia-ai-110000829.html", "source_name": "Business Wire", "published_at": "2026-07-09T11:00:00+00:00", "published_display": "09 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb sets July 29 call for Q2 2026 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOaFEzbS12dXh6X2o0anlvX1ZtSFFnazhueDI5bmFsUzBBQWpSUU9fbWtKck9RUThibkNwVGJxanFieUowZnFfdGViaFc2a3k2MklzV210QklkeF9MbVBoWGEyMkdlMWtUck53NndMVnlxaS0tSzI5R2xJUzBCTUxscHMtMGZWNk9mZ1N4WnNmNDNGTTZDUEhKYnVIUlJtZVlxamxrUmdMLThHT2pMQk9YcDBOWFZ0UUFhcG1xYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T11:15:00+00:00", "published_display": "06 Jul 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dry eye treatment tied to lower anxiety, better confidence in Bausch + Lomb survey", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQRF81dnNFVkNNUHFxU0xaVXRuRlc5cnBqMG5zWlJUR3BIa29YbEhlMkdTNEFfdklTYnlRVW1PM3kzV25BMHdaZUtSRG9VQXNpamtiOVdjTURRVF91MEhBeHhxSkpRbnZJRFRVYmZLTWRJSFVvU3FZN2RXakpjdFlGTnFvYXNHX3hldmloWVJjZlJqZlJGcFJaRW8ya3p6bkgyWGdHUGx2TWxWVGxGeV9EZW4zU0g0amc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb Corp updates investors on strategic focus, shares trade on NYSE", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPakl4aVA5REdXN1BfM0JYRjdVZWpKdGlnY0p1ZzhhUTlpWjdJQUFkVHdRT2FpVV9VN1ZKTThtMGh1VXpoaFJsVUdoWUxLWm43Q1BjMmtwclpmRlF4VmduV0ZMVFFsRkFhbjZ4YlpWZ0xweDg4MDZueHpkZXg3d3diVDhodDVLRkVTVWlwZUFueVg5eVRhVTlBTVdvRHpGYlI5bmdRb0pEMWNQR3BsallVMU5rUnBIQ0ZIRG96b3FOY184TmMtcERz?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-29T15:48:35+00:00", "published_display": "29 Jun 2026 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Blink Triple Care Preservative Free U.S. Launch", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Stocks Q1 Teardown: Bausch + Lomb (NYSE:BLCO) Vs The Rest", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPUFI2R08xV3JsZHYxbnFGcmk1Q3prRzBQVVlJNk5NTFlYOXBaczlzZE1PREIxb0loeUNQeUw3QWczNUowYXlEOU1KY1dTY2gybUQ5OEM0Z3Z2TlNleUVIRWJMc0VqZTdZcnVOZ2JBeUpIeFNCVjk3SVYxTmc5SG1RTjBHY2l3QkdxX09lZkpMekpYOElqQmJHc0dHUm8tVzJzSFZRaUdZZzNodTdyRjZz?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOb0ZWemZlT1UtTm9XVjdsZ3pONU54MXczTi1MN0p6NUIxVGdXTU1kZ25pbFprYjZlaEJWdC0tNkcwZU5SREoxWnQ3cjc4Slhmd1NEXzJkQkhMZkdLa2YyWDBuaE1ydHJORnR4NTcwemViOW5Bc2Z2M180LTFfbm5CWG9UYWdtRDAzcDBUZmpicndUaHozUFl6ZGN0UTZQUm8?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPXzd3QWhmdmpzRTUxb2diYTZvdGRiNGhyVVZoZXN1SmxMWnkzR18yVnV2MVFYU2JXMmlsT04tR3g2LU9uUGRmaUY3Sl9waHFhVnZ6WmhkZGQydld5bmFpZTcybDlYcnU5aHVnT2J2d19YNmJma21TbnF4S1FIVF9MMVRCaEtNQ1U3eVptb2JrSDlxb0oxWGpKVlhUS25HQXprWEFmd1NGdFRHREdKTGJxVDhITjNGT0paRm1IaXlSaWc?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reconsider Bausch + Lomb (BLCO) After Its 28% One-Year Rally?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQc3NiWDEyUjhSTUZhNVExeGg4OFJRMDZadDBGb2xJOVItMGVhc3dGbG90YmUzSGhyajBtQ0RodTY1MTlHejZXWHNwa2NiSWVhM2RaNFVlZ0ZSaFM0ck5EV0JBS2dvUUhOM20zQk40d2lnRVBhY0hlZ1o5VVFIXy13ZU5fYXI3eVpKam9mcGpEZTRLYXpuTzlkc2IzaFJEdw?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb brings full-range vision lens implant to Europe", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPUWozMmwyY2VNZ3VFODhMNGxldlY5WXpDTU9CcmtCQjhyZDFZVkVCenFfMGFtc09BdWgyVG41Z3QyNzJaZGszTWgxN25VNTg4dkd5MFpfaHVFdXRQdWlmcFE5NnhsbHR0VkJVMFRPalcyU0dtZE83b3hJdzAxM1pYUndrNllJZE1lT2FHdlpEQkdZWjZuSFFuV2s5YnFBTnpQVUFpUk4tN1BtNjR4V0pLazNmZTZOaWh5ZWZRNnh0a1c?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOd1pNRFRBVUF2RG5RNWNhSVJaWFM5aUFRVF9xSF8zVHVMcVBoSXdaRXJrbV8wLUFOS2tHOHIzZEhZSF9rZ2dVbVNIOEdEbE9GMmpsMEtIUE9OTGRjcUlyVnNSa2FyX3hjcmF2YTNDOGQ1UDVjMHI4ak44bUl1bnVoQ3VfSjZGMXR5T19xOWkzaUtSZ2NiMF80bUtvVWU?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Bausch + Lomb (BLCO) Valuation After Recent Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNLVo2UjhXRTNveWRreDFjell3UXdfNG1ITkVPNEx4eWw4Zl9JSEdiR3pRWmF0R1BYdDViaWE1ZzljM0FVU1M3b05IMG8xMFFmZ0dkNmZaU2I3dWtzVVJ6YWp4SDM3YW1WS1dHbWVNNjVXVkJTT0FtbW1CU1ptNDFYWlZLTWRvbTVtVnhzTlRPZmNHRDhpQWFqdGQ4STk?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPOEgwZkRBMVFxZEdfM0t2RzlZemdDaFY2a09WX1FaMzRBYzNxWFlmS1ktSllTeFJrMlBrZXZBeHpzdU9Hblp2Rk01M0U3bnI5YTVxdXFDV1Vmd0I1eWllanBRSzc4b1JOd01RcVJac3JuVGdONTlJUUx6Q285bV8yOXVIcEk?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Bausch + Lomb\u2019s glaucoma webinar on new treatments", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOV0JLRUJSWXVQRVVmWEUwZnlqMnNGaEZWVHFiOC1qSEdySGE2dFJPRjhTWmphU2MxQ1ROSWFCaDBvOExDVzd1WEFhWThXdmgzbWlpUFJZZGxjbnZkbVl1dHdXMHZIc3VqUE1KTUpVOWNxTllpZUVHdDFXUXBNRXhzcjFUMkpueUZuQUVfM0Rod0hWOHlaZGNHdUNMWjg?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T11:18:30+00:00", "published_display": "09 Mar 2026 11:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Latest Revenue And Net Loss Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQTC1aQWI2T2JjdHN6aWcyMHN4WVJqSTF4eEY0Z2U5OGwyNndxRkw3QTlYRDNkR2VEY1ZJNGVqNUNwbkR2NmtueFFPTGN2UFk2RU1vX1JrSHJpRUpEVkxhNGpQUEJhZWhRN29PTVk1WXlYOGFYRHNYdjhXVGdqUWh1dkNnMA?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb (BLCO) Reports Record Q4 2025 Financial Results Driven by Strong Pharmaceutical and Vision Care Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOelZmRXJOM2VuNDIwV1FiMWZsMzJtWXNqY3BISDNiRDFUd0FRS2lmNXVadkFlSmk5dGFHWU5RTFh6RzU1djBGcFI0N05NcmxkQl9lSl9UQTc1eEVKLXVZT0x0M3A4b2Vhb214ZXhfc1dyUUFuN3AyQjNpMk5SY0ZlOHRUQmk3ZEg2aUVsdEVmeVZuVDJaMks5QlB4V2YxYU1yMVZIMUJ1NWFiZFZjQXN0SXRxRUxVWjVZOXNRYlV3azN2am5XOVl1OUZaVWtLZDF3dFNjcERFMGZ5cUk?oc=5", "source_name": "Finviz", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats (NYSE:BLCO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNQnREYVY0SGRYMHloSldnY19DQWFFc1RPS1pzTWRfU0ZZenBPQVd3Rkt4M21fOUpCbVlGZzhiS2g1ZnJxX1JzMTZCdk9IX25icWdNTTNoZU5fZkRXV1dXekdwS190WWhtQVY2NURzT3pBZzNIVm82V2hmZV9YaEhGS1NoOXZ5bU1FNE1fSkg0M3BjalBtWG1QNjF4RjAxRzlzOE5j?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch & Lomb Earnings: Nice Results from Growth Momentum, Solid Execution, and Pipeline Investment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOR1ZVdGI1TmZuSm1LQldEVEplV3IzYS1hYnJVNURabjBoakktRUVjQndWZEVNRWNDSFB1YUh5ZkQ0akpDZkFELUM3UDVBbVdhOTNQWnY2ejRVMmtXTk1NdGotZlRJUVAtbmFzMjBfMDVJenUxYkhDbGhRYjlWcGZwUnA1WTgyMkhTYUItYTU4UkVsYV9HZ3JNR0lmeWRwTVc3N3hmYmpRYjdqQ0pJRHktVkpDNXNHRVZ2UGs5bDdnLUVNc1pTRVlRSQ?oc=5", "source_name": "Morningstar", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Bausch + Lomb\u2019s Mandatory AI Training Strategy Reshape the BLCO Execution Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOZWYteWRPYW1kMzJ1RHFfZElESlhTX0tIZDR5T0tJcXNWQk1WeTJJNDVnbXVmcjE5anA3LWRGSXpBdXo4dm1EUWUxdzB0d3dLS3JSUTBDYlBfLTg0Q0RzSm9yVzBpb3ZhT1IzTHYwVjJKX3UxRHFHc09fdkJ1RUZHZEVQTGFKdw?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE9UU1lyTUNJeDkxYWYxcFZrZFByR0YtTm1ib3NWRzdmM3FQNHRDbm85RS1VM3Z2UHZTZFZwWUU2enNpU1ZTcEJJU1pHTFlXckF6ZkR2TnBPUmxDcVN6dWgxMWVUN2JrdXZ0T1BrS2dqNDgtYVVYOGNXbm1jOWNPQQ?oc=5", "source_name": "Market source", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb announces U.S. launch of PreserVision AREDS 2 Formula Soft Gels Plus CoQ10", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNLUlyNnhDbEw0U3BVWXhwcHJhRWE0aTR3cGVjLUtNc2pxTXY0OHRnUFpMYzY3QTNYZTVnN2lEVFhBQzkzckdKNVU4Ry1tajR4b1h5aFVNT25QSFNqNHVKeEY4cEtoV3VCMi1aMEZDSkRfUlpkaVp0MHhvbzJWZkVMN3FjRDJSUGNSU2NwWENOZWRzUnZSeWZZcVZ5UGpFdzVRRE0tdXVXLWstclg0dDdVZ0VfekF1eXU1eXFzQXJ2eHc4Q3c?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2023-06-13T07:00:00+00:00", "published_display": "13 Jun 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb, Novaliq announce U.S. FDA filing acceptance for investigational treatment NOV03", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQUUNSbENub3cxY095eEdOUjVqTEU2V05nVjlWNVdfaGJGdDZiMkdZN3VtckdFTzVuQ0hlTDVTbXNnMDRsekdGNnBIX0tQNkFGR3VidE84cVNwc05mZGp1UVNhU1NSTm1wQTBMY0hRR04yU0l3UmVWaXRWdzFUemZ5cVBrSkE0SHh3Um5wNnk3RV9WVVZsT0JRWlJfb2tibVJNa25GaWxsUlY5RWhxXzhYb1lvMlIzSW9BbG16VWFpMENBZ0NOQi1WNU53?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2022-09-06T07:00:00+00:00", "published_display": "06 Sep 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb valued at $6.5 billion after stock ticks up in NYSE debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQU1pDSHhtUTc2enFfT01MN3kxNk54YWN3dFpiRGMtbEhNb05JbW5xYUdkN1FWUnBlN0lTNEFRYnNGMGtYMDdLYmgyczh5ZFB3T1FOQlVyWnRfdGhJcDdUREs4VHR1MEp4RkViTzB3MnZtNEw5Qm4yblFMRXRVWW5YZGhFeTE2bjF3OFBLQm8xZUVOMDAtaUxERDB4NUZRVG1vYWxNZ2sxVVNOTGYtcVlzWjFoRkZISjliQlhfZ2xn?oc=5", "source_name": "Reuters", "published_at": "2022-05-06T07:00:00+00:00", "published_display": "06 May 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BAUSCH + LOMB CORPORATION LAUNCHES AS A PUBLICLY TRADED COMPANY", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPd2xrb1gtZmhNV3M0eTJISTRaNktJdldhOUdTdGdOeC05MFVIbm1JMU5wLVdwX054UWg1Njk2aG1zYTdtdkdkYkxrM0RHQ3FET0FpQ3hDMXVZZ2xvOU5mam41OHlxM3dfZEdfSmF6dU9ndUxtcVlhWWZFZnVGNy1VaWNQXzlkT19VNWxVQlpJZGNZWExVdkxqZmJLeE1pVkxRLXlwSWltVmQtV0F5?oc=5", "source_name": "MultiVu", "published_at": "2022-05-06T07:00:00+00:00", "published_display": "06 May 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Bausch + Lomb Launches EyeGility\u2122 Inserter Preloaded IOL Delivery System in the United States", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bausch-lomb-launches-eyegility-inserter-110000251.html", "source_name": "Business Wire", "published_at": "2026-07-16T11:00:00+00:00", "published_display": "16 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ophthalmology-devices-market-report-released-113000874.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T11:30:00+00:00", "published_display": "13 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BLCO Stock Drops After-Hours \u2014 Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQcVR2TktPdTV5TFB1LXBsS0FiVklodV9kZlZsc0U1QTNyQ2dvT2lXa1NIZFlVRTZORGFDS21rNll4bDM2SC1GdWlXcm45TENtQnUwcVAyd1NwVnA0V1VmM255OXBwZUNGQmItWEMyakJsYnJxaDNoWUFud25XQzdiVldkZldsaDFkWTlqazAyT0xzVDR0RkpLZXN2ZHRpRE83RTVqWk9TV2dtS1FTejhBYlBaMEpSRS1RMHl1SGlUMGNyQWp1T1JmMjVFeXNtUHJaamZQbw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-12T16:31:13+00:00", "published_display": "12 Jul 2026 16:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPYmtwbXNJUjlRc0owMHd3MDBQOFFhM1ppZWZmSkZVTVV0M1NVdDRKS2s5SDdaQndDZk81WHRXNTNZNGNVSHNPbVBQdURxdGhQSUxsLXRRRnZMZC1rSS1qXzMyUlFocTZ6TFA2OGNYSDBVeUtGUnpJWG1CZlRLV2U5ZmE0bWhIUGtmOXh6bExjZUlCanZJQ3c?oc=5", "source_name": "Market source", "published_at": "2026-07-10T21:27:20+00:00", "published_display": "10 Jul 2026 21:27", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Bausch + Lomb Corporation \u2013 NYSE:BLCO", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNOE05YnQ4Sk9xNVp1SXBsWUtYaVB3WFVhaEtwTkprbEY4TG5JVHJ4THV5ZlFtaFVVejBSVUc3d09kbW13VktnVl80eFpkUWstcWo3QzBLeFBCTTlvUmVkODlxaXdCeTJacUZoU2pNaEtTdmQtbjdsZW95MWpnbVVmU0tfblFOQjVUVU8wVEZsVU9ZWHBrd3hxd2dkc0xFRTA?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T11:37:40+00:00", "published_display": "10 Jul 2026 11:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb (BLCO) Could Be 57% Below Fair Value After Product Updates", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bausch-lomb-blco-could-57-061154578.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T06:11:54+00:00", "published_display": "10 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb Says Phase 2 Trial for Glaucoma Neuroprotective Candidate Fails to Meet Primary Endpoint", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bausch-lomb-says-phase-2-205707845.html", "source_name": "MT Newswires", "published_at": "2026-07-09T20:57:07+00:00", "published_display": "09 Jul 2026 20:57", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bausch-lomb-announces-phase-2-203000317.html", "source_name": "Business Wire", "published_at": "2026-07-09T20:30:00+00:00", "published_display": "09 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb Introduces Orphia\u2122, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bausch-lomb-introduces-orphia-ai-110000829.html", "source_name": "Business Wire", "published_at": "2026-07-09T11:00:00+00:00", "published_display": "09 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb sets July 29 call for Q2 2026 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOaFEzbS12dXh6X2o0anlvX1ZtSFFnazhueDI5bmFsUzBBQWpSUU9fbWtKck9RUThibkNwVGJxanFieUowZnFfdGViaFc2a3k2MklzV210QklkeF9MbVBoWGEyMkdlMWtUck53NndMVnlxaS0tSzI5R2xJUzBCTUxscHMtMGZWNk9mZ1N4WnNmNDNGTTZDUEhKYnVIUlJtZVlxamxrUmdMLThHT2pMQk9YcDBOWFZ0UUFhcG1xYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T11:15:00+00:00", "published_display": "06 Jul 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dry eye treatment tied to lower anxiety, better confidence in Bausch + Lomb survey", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQRF81dnNFVkNNUHFxU0xaVXRuRlc5cnBqMG5zWlJUR3BIa29YbEhlMkdTNEFfdklTYnlRVW1PM3kzV25BMHdaZUtSRG9VQXNpamtiOVdjTURRVF91MEhBeHhxSkpRbnZJRFRVYmZLTWRJSFVvU3FZN2RXakpjdFlGTnFvYXNHX3hldmloWVJjZlJqZlJGcFJaRW8ya3p6bkgyWGdHUGx2TWxWVGxGeV9EZW4zU0g0amc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb Corp updates investors on strategic focus, shares trade on NYSE", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPakl4aVA5REdXN1BfM0JYRjdVZWpKdGlnY0p1ZzhhUTlpWjdJQUFkVHdRT2FpVV9VN1ZKTThtMGh1VXpoaFJsVUdoWUxLWm43Q1BjMmtwclpmRlF4VmduV0ZMVFFsRkFhbjZ4YlpWZ0xweDg4MDZueHpkZXg3d3diVDhodDVLRkVTVWlwZUFueVg5eVRhVTlBTVdvRHpGYlI5bmdRb0pEMWNQR3BsallVMU5rUnBIQ0ZIRG96b3FOY184TmMtcERz?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-29T15:48:35+00:00", "published_display": "29 Jun 2026 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Blink Triple Care Preservative Free U.S. Launch", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Stocks Q1 Teardown: Bausch + Lomb (NYSE:BLCO) Vs The Rest", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPUFI2R08xV3JsZHYxbnFGcmk1Q3prRzBQVVlJNk5NTFlYOXBaczlzZE1PREIxb0loeUNQeUw3QWczNUowYXlEOU1KY1dTY2gybUQ5OEM0Z3Z2TlNleUVIRWJMc0VqZTdZcnVOZ2JBeUpIeFNCVjk3SVYxTmc5SG1RTjBHY2l3QkdxX09lZkpMekpYOElqQmJHc0dHUm8tVzJzSFZRaUdZZzNodTdyRjZz?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOb0ZWemZlT1UtTm9XVjdsZ3pONU54MXczTi1MN0p6NUIxVGdXTU1kZ25pbFprYjZlaEJWdC0tNkcwZU5SREoxWnQ3cjc4Slhmd1NEXzJkQkhMZkdLa2YyWDBuaE1ydHJORnR4NTcwemViOW5Bc2Z2M180LTFfbm5CWG9UYWdtRDAzcDBUZmpicndUaHozUFl6ZGN0UTZQUm8?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPXzd3QWhmdmpzRTUxb2diYTZvdGRiNGhyVVZoZXN1SmxMWnkzR18yVnV2MVFYU2JXMmlsT04tR3g2LU9uUGRmaUY3Sl9waHFhVnZ6WmhkZGQydld5bmFpZTcybDlYcnU5aHVnT2J2d19YNmJma21TbnF4S1FIVF9MMVRCaEtNQ1U3eVptb2JrSDlxb0oxWGpKVlhUS25HQXprWEFmd1NGdFRHREdKTGJxVDhITjNGT0paRm1IaXlSaWc?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reconsider Bausch + Lomb (BLCO) After Its 28% One-Year Rally?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQc3NiWDEyUjhSTUZhNVExeGg4OFJRMDZadDBGb2xJOVItMGVhc3dGbG90YmUzSGhyajBtQ0RodTY1MTlHejZXWHNwa2NiSWVhM2RaNFVlZ0ZSaFM0ck5EV0JBS2dvUUhOM20zQk40d2lnRVBhY0hlZ1o5VVFIXy13ZU5fYXI3eVpKam9mcGpEZTRLYXpuTzlkc2IzaFJEdw?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb brings full-range vision lens implant to Europe", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPUWozMmwyY2VNZ3VFODhMNGxldlY5WXpDTU9CcmtCQjhyZDFZVkVCenFfMGFtc09BdWgyVG41Z3QyNzJaZGszTWgxN25VNTg4dkd5MFpfaHVFdXRQdWlmcFE5NnhsbHR0VkJVMFRPalcyU0dtZE83b3hJdzAxM1pYUndrNllJZE1lT2FHdlpEQkdZWjZuSFFuV2s5YnFBTnpQVUFpUk4tN1BtNjR4V0pLazNmZTZOaWh5ZWZRNnh0a1c?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOd1pNRFRBVUF2RG5RNWNhSVJaWFM5aUFRVF9xSF8zVHVMcVBoSXdaRXJrbV8wLUFOS2tHOHIzZEhZSF9rZ2dVbVNIOEdEbE9GMmpsMEtIUE9OTGRjcUlyVnNSa2FyX3hjcmF2YTNDOGQ1UDVjMHI4ak44bUl1bnVoQ3VfSjZGMXR5T19xOWkzaUtSZ2NiMF80bUtvVWU?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Bausch + Lomb (BLCO) Valuation After Recent Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNLVo2UjhXRTNveWRreDFjell3UXdfNG1ITkVPNEx4eWw4Zl9JSEdiR3pRWmF0R1BYdDViaWE1ZzljM0FVU1M3b05IMG8xMFFmZ0dkNmZaU2I3dWtzVVJ6YWp4SDM3YW1WS1dHbWVNNjVXVkJTT0FtbW1CU1ptNDFYWlZLTWRvbTVtVnhzTlRPZmNHRDhpQWFqdGQ4STk?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPOEgwZkRBMVFxZEdfM0t2RzlZemdDaFY2a09WX1FaMzRBYzNxWFlmS1ktSllTeFJrMlBrZXZBeHpzdU9Hblp2Rk01M0U3bnI5YTVxdXFDV1Vmd0I1eWllanBRSzc4b1JOd01RcVJac3JuVGdONTlJUUx6Q285bV8yOXVIcEk?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Bausch + Lomb\u2019s glaucoma webinar on new treatments", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOV0JLRUJSWXVQRVVmWEUwZnlqMnNGaEZWVHFiOC1qSEdySGE2dFJPRjhTWmphU2MxQ1ROSWFCaDBvOExDVzd1WEFhWThXdmgzbWlpUFJZZGxjbnZkbVl1dHdXMHZIc3VqUE1KTUpVOWNxTllpZUVHdDFXUXBNRXhzcjFUMkpueUZuQUVfM0Rod0hWOHlaZGNHdUNMWjg?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T11:18:30+00:00", "published_display": "09 Mar 2026 11:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Latest Revenue And Net Loss Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQTC1aQWI2T2JjdHN6aWcyMHN4WVJqSTF4eEY0Z2U5OGwyNndxRkw3QTlYRDNkR2VEY1ZJNGVqNUNwbkR2NmtueFFPTGN2UFk2RU1vX1JrSHJpRUpEVkxhNGpQUEJhZWhRN29PTVk1WXlYOGFYRHNYdjhXVGdqUWh1dkNnMA?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb (BLCO) Reports Record Q4 2025 Financial Results Driven by Strong Pharmaceutical and Vision Care Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOelZmRXJOM2VuNDIwV1FiMWZsMzJtWXNqY3BISDNiRDFUd0FRS2lmNXVadkFlSmk5dGFHWU5RTFh6RzU1djBGcFI0N05NcmxkQl9lSl9UQTc1eEVKLXVZT0x0M3A4b2Vhb214ZXhfc1dyUUFuN3AyQjNpMk5SY0ZlOHRUQmk3ZEg2aUVsdEVmeVZuVDJaMks5QlB4V2YxYU1yMVZIMUJ1NWFiZFZjQXN0SXRxRUxVWjVZOXNRYlV3azN2am5XOVl1OUZaVWtLZDF3dFNjcERFMGZ5cUk?oc=5", "source_name": "Finviz", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats (NYSE:BLCO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNQnREYVY0SGRYMHloSldnY19DQWFFc1RPS1pzTWRfU0ZZenBPQVd3Rkt4M21fOUpCbVlGZzhiS2g1ZnJxX1JzMTZCdk9IX25icWdNTTNoZU5fZkRXV1dXekdwS190WWhtQVY2NURzT3pBZzNIVm82V2hmZV9YaEhGS1NoOXZ5bU1FNE1fSkg0M3BjalBtWG1QNjF4RjAxRzlzOE5j?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch & Lomb Earnings: Nice Results from Growth Momentum, Solid Execution, and Pipeline Investment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOR1ZVdGI1TmZuSm1LQldEVEplV3IzYS1hYnJVNURabjBoakktRUVjQndWZEVNRWNDSFB1YUh5ZkQ0akpDZkFELUM3UDVBbVdhOTNQWnY2ejRVMmtXTk1NdGotZlRJUVAtbmFzMjBfMDVJenUxYkhDbGhRYjlWcGZwUnA1WTgyMkhTYUItYTU4UkVsYV9HZ3JNR0lmeWRwTVc3N3hmYmpRYjdqQ0pJRHktVkpDNXNHRVZ2UGs5bDdnLUVNc1pTRVlRSQ?oc=5", "source_name": "Morningstar", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Bausch + Lomb\u2019s Mandatory AI Training Strategy Reshape the BLCO Execution Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOZWYteWRPYW1kMzJ1RHFfZElESlhTX0tIZDR5T0tJcXNWQk1WeTJJNDVnbXVmcjE5anA3LWRGSXpBdXo4dm1EUWUxdzB0d3dLS3JSUTBDYlBfLTg0Q0RzSm9yVzBpb3ZhT1IzTHYwVjJKX3UxRHFHc09fdkJ1RUZHZEVQTGFKdw?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE9UU1lyTUNJeDkxYWYxcFZrZFByR0YtTm1ib3NWRzdmM3FQNHRDbm85RS1VM3Z2UHZTZFZwWUU2enNpU1ZTcEJJU1pHTFlXckF6ZkR2TnBPUmxDcVN6dWgxMWVUN2JrdXZ0T1BrS2dqNDgtYVVYOGNXbm1jOWNPQQ?oc=5", "source_name": "Market source", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb announces U.S. launch of PreserVision AREDS 2 Formula Soft Gels Plus CoQ10", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNLUlyNnhDbEw0U3BVWXhwcHJhRWE0aTR3cGVjLUtNc2pxTXY0OHRnUFpMYzY3QTNYZTVnN2lEVFhBQzkzckdKNVU4Ry1tajR4b1h5aFVNT25QSFNqNHVKeEY4cEtoV3VCMi1aMEZDSkRfUlpkaVp0MHhvbzJWZkVMN3FjRDJSUGNSU2NwWENOZWRzUnZSeWZZcVZ5UGpFdzVRRE0tdXVXLWstclg0dDdVZ0VfekF1eXU1eXFzQXJ2eHc4Q3c?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2023-06-13T07:00:00+00:00", "published_display": "13 Jun 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb, Novaliq announce U.S. FDA filing acceptance for investigational treatment NOV03", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQUUNSbENub3cxY095eEdOUjVqTEU2V05nVjlWNVdfaGJGdDZiMkdZN3VtckdFTzVuQ0hlTDVTbXNnMDRsekdGNnBIX0tQNkFGR3VidE84cVNwc05mZGp1UVNhU1NSTm1wQTBMY0hRR04yU0l3UmVWaXRWdzFUemZ5cVBrSkE0SHh3Um5wNnk3RV9WVVZsT0JRWlJfb2tibVJNa25GaWxsUlY5RWhxXzhYb1lvMlIzSW9BbG16VWFpMENBZ0NOQi1WNU53?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2022-09-06T07:00:00+00:00", "published_display": "06 Sep 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bausch + Lomb valued at $6.5 billion after stock ticks up in NYSE debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQU1pDSHhtUTc2enFfT01MN3kxNk54YWN3dFpiRGMtbEhNb05JbW5xYUdkN1FWUnBlN0lTNEFRYnNGMGtYMDdLYmgyczh5ZFB3T1FOQlVyWnRfdGhJcDdUREs4VHR1MEp4RkViTzB3MnZtNEw5Qm4yblFMRXRVWW5YZGhFeTE2bjF3OFBLQm8xZUVOMDAtaUxERDB4NUZRVG1vYWxNZ2sxVVNOTGYtcVlzWjFoRkZISjliQlhfZ2xn?oc=5", "source_name": "Reuters", "published_at": "2022-05-06T07:00:00+00:00", "published_display": "06 May 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BAUSCH + LOMB CORPORATION LAUNCHES AS A PUBLICLY TRADED COMPANY", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPd2xrb1gtZmhNV3M0eTJISTRaNktJdldhOUdTdGdOeC05MFVIbm1JMU5wLVdwX054UWg1Njk2aG1zYTdtdkdkYkxrM0RHQ3FET0FpQ3hDMXVZZ2xvOU5mam41OHlxM3dfZEdfSmF6dU9ndUxtcVlhWWZFZnVGNy1VaWNQXzlkT19VNWxVQlpJZGNZWExVdkxqZmJLeE1pVkxRLXlwSWltVmQtV0F5?oc=5", "source_name": "MultiVu", "published_at": "2022-05-06T07:00:00+00:00", "published_display": "06 May 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 72, "total_relevant": 32, "sentiment_summary": {"positive": 3, "negative": 4, "neutral": 25, "score": 50, "total": 32, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 13.0, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 5.1, "count": 8}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 3, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 16.23, "latest_week": "2026-07-10", "one_week_move": -5.4, "four_week_move": 7.6, "twelve_week_move": -3.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.358392, "market_dynamics_buy_signal": false, "relative_strength": -7.897754, "fair_value_gap": 1.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.5177, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.4% over one week, +7.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 4}, {"label": "Business Wire", "count": 3}, {"label": "Ophthalmology Times Europe", "count": 2}, {"label": "GlobeNewswire", "count": 1}, {"label": "Stocktwits", "count": 1}, {"label": "TradingView", "count": 1}, {"label": "Simply Wall St.", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 32}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 8}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "32", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-5.4% over one week, +7.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Bausch + Lomb Launches EyeGility\u2122 Inserter Preloaded IOL Delivery System in the United States"}], "updated_at": "2026-07-16T11:42:36.777670+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}